Minnesota SF4189 directs the Commissioner of Health to study and report on activities to support innovations in cell and gene therapy for rare.

Minnesota SF4189 mandates the Commissioner of Health to conduct a comprehensive study on activities to support innovations in cell and gene therapy for rare diseases. The study will assess the state's current capacity and strategies to support innovations, including infrastructure, workforce needs, and policies regarding covering and paying for cell and gene therapies. The report, due by January 1, 2028, will also include recommendations for state investments, policy changes, and potential federal funding opportunities.

Minnesota SF4189 directs the Commissioner of Health to study and report on activities to support innovations in cell and gene therapy for rare.

Minnesota SF4189 mandates the Commissioner of Health to conduct a comprehensive study on activities to support innovations in cell and gene therapy for rare diseases. The study will assess the state's current capacity and strategies to support innovations, including infrastructure, workforce needs, and policies regarding covering and paying for cell and gene therapies. The report, due by January 1, 2028, will also include recommendations for state investments, policy changes, and potential federal funding opportunities.